Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them
or deliver tumor-killing substances to them without harming normal cells. Combining
chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody
therapy in treating women with recurrent or metastatic breast cancer.